• Doxorubicin and SMYD2: A Smarter Resistance Strategy

  2026-08-26

  Doxorubicin is more than a cytotoxic benchmark: paired with SMYD2 biology, it becomes a strategic probe of DNA damage, epigenetic state, and multidrug resistance. This translational framework connects Adriamycin mechanism with actionable experimental design in renal cell carcinoma and broader oncology research.

• Matrine: From Cell Death to Assay Design

  2026-08-26

  Matrine, also indexed as Sophocarpidine, is a multifunctional Sophora alkaloid with emerging activity against tumor stemness, apoptosis, and inflammation. This article translates recent thymoma findings into an evidence-aware assay strategy while distinguishing validated observations from mechanistic hypotheses.

• Super-Enhancer Control of KLF6 in Adipogenesis

  2026-08-25

  Nguyen et al. identify a KLF6-proximal super-enhancer as an active regulatory hub during the adipogenic differentiation of human adipose-derived stem cells. Their experiments connect PPARγ, enhancer RNA, p300, and HDAC3 to a KLF6–DLK1 regulatory circuit, while using JQ1 to test the functional importance of BET-associated enhancer activity.

• CPI-613 Workflows for Tumor Metabolism Studies

  2026-08-25

  CPI-613 enables controlled interrogation of mitochondrial carbon metabolism, apoptosis, and chemotherapy sensitivity in cancer models. This practical guide connects dose-response assays with PDHA1-centered tumor–macrophage experiments and troubleshooting strategies.

• Nanoparticle mRNA Delivery Reverses Trastuzumab Resistance

  2026-08-24

  Dong and colleagues developed a tumor-microenvironment-responsive nanoparticle system for systemic delivery of PTEN mRNA to trastuzumab-resistant breast cancer. Their findings connect stimulus-responsive delivery with restoration of PTEN expression and inhibition of PI3K/Akt signaling, providing a preclinical framework for addressing resistance beyond HER2 blockade alone.

• Z-VDVAD-FMK: A Caspase-2 Pathway Probe

  2026-08-23

  Z-VDVAD-FMK is an irreversible, cell-permeable caspase-2 probe for separating mitochondrial apoptosis from caspase-1-driven pyroptosis. This article applies the reagent to assay interpretation in HOXC8-linked lung cancer research, emphasizing orthogonal readouts and pathway-specific controls.

• FCCP: Reading Mitochondrial Stress in Context

  2026-08-22

  FCCP is a powerful mitochondrial uncoupler, but its most informative use comes from interpreting oxygen flux, ATP loss, HIF signaling, and CO2-dependent communication together. This guide develops a cross-disciplinary assay framework for mitochondrial biology research and metabolic regulation studies.

• Hypoxia and Immunometabolism in the Tumor Microenvironment

  2026-08-21

  This 2025 Cancer Letters review frames tumor hypoxia and immunometabolism as a reciprocal process in which oxygen limitation, nutrient competition, and immune dysfunction reinforce an immunosuppressive tumor microenvironment. Its main practical contribution is a systems-level framework for connecting HIF signaling and metabolic reprogramming with tumor progression and for designing more informative metabolism-focused therapeutic studies.

• Cy3 RNA Labeling Kit: HyperScribe T7 Plus

  2026-08-21

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus supports in vitro transcription of randomly Cy3-modified RNA probes for fluorescence-based research assays. It is intended for workflows such as in situ hybridization and Northern blot hybridization, not diagnostic, therapeutic, or clinical use.

• ARCA Cy5 EGFP mRNA: Decoding Delivery in Macrophages

  2026-08-20

  ARCA Cy5 EGFP mRNA (5-moUTP) enables researchers to separate nanoparticle uptake from productive translation in macrophage studies. This guide presents an assay framework grounded in carbohydrate-targeted gene delivery research.

• PYR-41 and the E1 Control Point in Viral Immunity

  2026-08-20

  A thought-leadership guide to using PYR-41 as a mechanistic probe of ubiquitin-dependent protein control, NF-κB signaling, inflammation, and viral immune evasion. The article connects recent IBDV findings on VP3-driven IRF7 degradation with practical assay design while distinguishing hypothesis generation from translational evidence.

• GDC-0994: From ERK Biology to Translational Design

  2026-08-19

  GDC-0994 is a potent, selective ERK1/2 inhibitor that enables researchers to connect pathway-level target engagement with tumor-cell phenotypes and emerging cholestasis models. This thought-leadership guide examines its mechanistic rationale, experimental design considerations, competitive position, and translational boundaries.

• Partial BACE1 Inhibition and Synaptic Transmission

  2026-08-19

  Satir et al. tested whether moderate β-secretase inhibition can lower amyloid-β secretion without impairing neuronal communication. Using primary rat cortical cultures and optical electrophysiology, the study found that reductions below 50% were compatible with preserved synaptic transmission, whereas stronger inhibition was associated with functional suppression.

• Toremifene in Prostate Cancer Research Workflows

  2026-08-18

  Toremifene provides a practical estrogen-receptor perturbation tool for connecting hormone response, cell growth, and metastatic phenotypes in prostate cancer models. This workflow pairs dose–response assays with calcium signaling and TSPAN18–STIM1 mechanistic readouts, helping researchers distinguish pathway effects from nonspecific toxicity.

• Ciclesonide and the Next Logic of Inflammation

  2026-08-18

  Ciclesonide illustrates how prodrug activation, glucocorticoid receptor binding, and lung-cell biology can be translated into a more rigorous respiratory research strategy. In parallel, new ERAD-engaging chimeras reveal a distinct route for targeted protein degradation, creating a useful conceptual bridge without implying that Ciclesonide is itself an ERAD degrader.

456 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page